MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers18040653

Медицинская библиотека · Cancers · 2026

Real-World Data on the Safety and Efficacy of SBRT for Central and Ultra-Central Lung Tumors: A Retrospective Multi-Center Cohort.

Zygogianni Anna, Kougioumtzopoulou Andromachi, Platoni Kalliopi, Protopapa Maria, Liakouli Zoi, Koukourakis Ioannis M, Alexiou Despoina, Stroubinis Theodoros, Armpilia Christina, Antypas Christos, Psarras Michalis, Stasinou Despoina, Georgakopoulos Ioannis, Kouloulias Vasileios

СтатьяПеревод пока не подготовлен

Аннотация

Background/

Objectives

The use of stereotactic body radiotherapy (SBRT) for centrally and ultra-centrally located early-stage non-small cell lung cancer (NSCLC) remains clinically challenging due to the proximity of critical mediastinal organs at risk and the limited prospective evidence, particularly for ultra-central disease. Real-world data are needed to better define the safety and efficacy of SBRT when delivered according to contemporary protocol-based planning principles.

Methods

This retrospective cohort study included patients treated at two radiotherapy centers, with centralized follow-up and outcome adjudication at a single academic institution. We evaluated patients with centrally or ultra-centrally located, early-stage NSCLC treated with SBRT according to dose-fractionation and planning principles derived from the NRG Oncology/RTOG 0813 protocol. Tumors were classified as central or ultra-central according to the International Association for the Study of Lung Cancer and HILUS definitions, respectively. The prescribed dose was 50 Gy in five fractions. Primary endpoints were treatment-related toxicity and local progression-free survival (LPFS). Secondary endpoints included overall survival (OS), progression-free survival (PFS), and dosimetric outcomes. Survival endpoints were analyzed using the Kaplan-Meier method.

Results

Seventy-eight patients were included, of whom 52 had centrally located and 26 ultra-centrally located tumors. Median follow-up was 57 months. The overall objective response rate was 92.3%. The estimated 4-year LPFS was 97.4% for the entire cohort, with rates of 100% for central and 91.6% for ultra-central tumors (p < 0.001). Four-year OS was 98.7%, with no treatment-related deaths observed. Treatment-related toxicity was minimal, with grade ≥ 2 events occurring in only one patient (1.3%) and no grade ≥ 3 toxicity. All treatment plans met predefined organ-at-risk dose constraints.

Conclusions

In this real-world cohort, SBRT delivered according to RTOG 0813 planning principles achieved excellent local control with minimal clinically relevant toxicity in patients with centrally and ultra-centrally located early-stage NSCLC. These findings support the safe implementation of SBRT in carefully selected patients when stringent organ-at-risk constraints and conservative treatment planning are employed.

Для цитирования: Zygogianni Anna, Kougioumtzopoulou Andromachi, Platoni Kalliopi, Protopapa Maria, Liakouli Zoi, Koukourakis Ioannis M, Alexiou Despoina, Stroubinis Theodoros, Armpilia Christina, Antypas Christos, Psarras Michalis, Stasinou Despoina, Georgakopoulos Ioannis, Kouloulias Vasileios. Real-World Data on the Safety and Efficacy of SBRT for Central and Ultra-Central Lung Tumors: A Retrospective Multi-Center Cohort.. Cancers. 2026. DOI: 10.3390/cancers18040653.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.